Celltrion slides to third in race for Roche rituximab biosimilar with planned ... Financial Times Celltrion, (KOSDAQ: 068270) the South Korean biosimilars developer, now looks to be third in the race to develop a biosimilar version of Roche's (VTX:ROG) blockbuster Rituxan/Mabthera (rituximab), after it has emerged it does not actually plan to start ... Report: Don't count Celltrion out of Rituxan biosim race |
